BioStock Investor Meeting: Lipum presents

Biopharmaceutical company Lipum is developing a new biological drug for the treatment of rheumatoid arthritis (RA) and other chronic inflammatory diseases. The next major goal is to initiate a first clinical study with the candidate SOL-116. CEO Einar Pontén attended the BioStock Investor Meeting in Stockholm and told us more about the way forward.

See the presentation at biostock.se:

https://www.biostock.se/en/2022/09/biostock-investor-meeting-lipum-presents/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/